Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: Dermapharm Holding SE: binding offer to acquire Arkopharma Group

eqs_en 
0 0 30.07.22
DGAP-Adhoc: Dermapharm Holding SE: binding offer to acquire Arkopharma Group
 

DGAP-Ad-hoc: Dermapharm Holding SE / Key word(s): Takeover
Dermapharm Holding SE: binding offer to acquire Arkopharma Group

30-Jul-2022 / 20:22 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation – MAR)


Dermapharm Holding SE: binding offer to acquire Arkopharma Group

Grünwald, July 30, 2022 – Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), offered to acquire 100% of the shares in Apharma TopCo SAS, headquartered in Carros, France, from private equity firm Montagu and minority shareholders of the target, for a purchase price approximating EUR 450 million.

Apharma TopCo SAS is the holding company of the Arkopharma Group, a provider of herbal OTC products and dietary supplements in France and other European countries. In the financial year 2021, Arkopharma Group achieved sales of approximately EUR 191 million. For the current financial year 2022, it forecasts sales of slightly over EUR 200 million.

The execution of the corresponding share purchase agreement is subject to the consultation of the works council of certain French companies of the Arkopharma Group. The Management Board expects the transaction to be completed at the beginning of January 2023.

>End of the Ad hoc announcement <

 

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Phone: +49 (0)89 – 64186-233
E-Mail: [email protected]

 

30-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: [email protected]
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1409691

 
End of Announcement DGAP News Service

1409691  30-Jul-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1409691&application_name=news&site_id=sharewise

Dermapharm Holding SE Stock

€35.30
1.150%
Dermapharm Holding SE gained 1.150% today.
Our community is currently high on Dermapharm Holding SE with 5 Buy predictions and 0 Sell predictions.
As a result the target price of 55 € shows a very positive potential of 55.81% compared to the current price of 35.3 € for Dermapharm Holding SE.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!